Shares in Teva Pharmaceutical (NYSE:TEVA) fell slightly in pre-market activity today after the pharmaceutical company beat earnings expectations on Wall Street with its 1st quarter results. The Israel-based company posted profits of $641 million on sales of $5.63 billion for the 3 months ended March 31, for bottom-line growth of 1.3% on sales growth of 17% compared […]
Teva Pharmaceuticals
scPharmaceuticals names Tucker as CEO | Personnel Moves – May 1, 2017
scPharmaceuticals said in late April that it named pharma-veteran John Tucker as president & CEO, effective immediately. Tucker was also elected to the company’s board of directors. Tucker formerly served as CEO of Alcresta, where he led regulatory and financing strategies for the company’s 1st product approval and launch. He also worked as Incline Therapeutics’ […]
Teva launches AirDuo RespiClick, generic inhaled asthma therapies
Teva Pharmaceutical (NYSE:TEVA) said today that it launched the AirDuo RespiClick inhalation therapy and its authorized generic in the U.S. for asthma patients who are uncontrolled on an inhaled corticosteroid. AirDuo RespiClick and the generic are fixed-dose combination therapies contained fluticasone propionate and salmeterol – the same active ingredients as Advair. The therapies are delivered […]
Demand for EpiPen alternatives jumps as states consider access legislation
Prescriptions for EpiPen alternatives such as Kaléo Inc.‘s Auvi-Q device have quadrupled since the beginning of this year, according to data from the Athenahealth Network. The demand for cheaper alternative devices is likely driven by revelations that Mylan (NSDQ:MYL) hiked the price of its EpiPen emergency allergy injector by 500% since it acquired the device in 2007. Generic […]
Teva Pharmaceutical beats Q4 earnings, sales estimates
Shares in Teva Pharmaceutical (NYSE:TEVA) rose today after the pharmaceutical company met expectations on Wall Street with its 4th quarter results. The Israel-based company posted a loss of -$974 million on sales of $6.49 billion for the 3 months ended Dec. 31, for bottom-line loss of -296% on sales growth of 33% compared with the same period last […]
Teva Pharma CEO Vigodman steps down | Personnel Moves | February 7, 2017
Teva Pharmaceuticals (NYSE:TEVA) said this week that CEO Erez Vigodman has stepped down from their position at the head of the world’s biggest generic drugmaker. Vigodman’s exit from the company will take effect immediately, with board chair Yitzhak Peterburg taking on the interim role of chief exec. Israel-based Teva has seen shares plummet after a series of […]
Teva wins FDA nod for inhaled asthma medications
Teva Pharmaceuticals (NYSE:TEVA) said today that the FDA approved 2 inhaled asthma medications to be delivered using the company’s RespiClick breath-activated, multi-dose dry powder inhaler. The products, AirDuo RespiClick and ArmonAir RespiClick, are indicated for use in asthma patients as young as 12 years old. The Jerusalem-based company’s AirDuo RespiClick is a fixed dose combination of […]
Teva coughs up $519m to settle overseas bribery charges
Teva Pharmaceuticals (NYSE:TEVA) will pay $519 million to settle allegations that the company bribed overseas officials in Mexico, Russia and Ukraine to promote its products, according to the U.S. Justice Dept. The department reported that the millions of dollars in bribes occurred for more than a decade. The pharmaceutical giant agreed to $238 million to […]
Bipartisan report from senators calls for drug pricing reform
The U.S. Senate Special Committee on Aging released a bipartisan report yesterday suggesting ways to respond to spikes in drug pricing. The report comes after a months-long investigation spearheaded by Sens. Susan Collins (R-Maine) and Claire McCaskill (D-Missouri). The senators wrote that massive spikes in drug prices are “gouging” patients and that lawmakers should respond. […]
Mylan launches first generic EpiPen as state AGs sue generics makers for price collusion
Mylan (NSDQ:MYL) launched its 1st generic EpiPen emergency allergy treatment 1 day after attorney generals from 20 states filed a civil complaint against Mylan, Teva Pharmaceuticals (NYSE:TEVA), and 4 other generic drug makers. The complaint alleges that the companies co-conspired in informal gatherings, calls and text messages to fix the price for glyburide, a diabetes drug, and doxycycline […]
Ex pharma execs first to be charged in generic drug pricing case
Former Heritage Pharmaceuticals CEO Jeffrey Glazer and ex-president Jason Malek were hit yesterday with the 1st criminal charges from a 2-year federal investigation in an ongoing generic drug pricing case. The 2 former executives were charged by federal authorities with price collusion for doxycycline hyclate, a widely used antibiotic, and a diabetes therapy called glyburide […]